KIT as a therapeutic target in metastatic melanoma
RD Carvajal, CR Antonescu, JD Wolchok… - Jama, 2011 - jamanetwork.com
Context Some melanomas arising from acral, mucosal, and chronically sun-damaged sites
harbor activating mutations and amplification of the type III transmembrane receptor tyrosine
kinase KIT. We explored the effects of KIT inhibition using imatinib mesylate in this molecular
subset of disease. Objective To assess clinical effects of imatinib mesylate in patients with
melanoma harboring KIT alterations. Design, Setting, and Patients A single-group, open-
label, phase 2 trial at 1 community and 5 academic oncology centers in the United States of …
harbor activating mutations and amplification of the type III transmembrane receptor tyrosine
kinase KIT. We explored the effects of KIT inhibition using imatinib mesylate in this molecular
subset of disease. Objective To assess clinical effects of imatinib mesylate in patients with
melanoma harboring KIT alterations. Design, Setting, and Patients A single-group, open-
label, phase 2 trial at 1 community and 5 academic oncology centers in the United States of …